# Nabla Bio

**Source:** https://geo.sig.ai/brands/nabla-bio  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** nablabio.com  
**Last Updated:** 2026-04-14

## Summary

AI antibody design platform targeting undruggable GPCRs and ion channels; $37M raised with $550M+ in AstraZeneca, BMS, and Takeda partnership milestones led by Radical Ventures.

## Company Overview

Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.

Nabla Bio's generative protein design platform creates novel antibody architectures specifically optimized for binding to multipass membrane proteins — using deep learning to design proteins that can access and bind the exposed loops and domains of these structurally complex targets that conventional antibody discovery methods fail to address reliably. GPCRs alone are targets of approximately 34% of all FDA-approved drugs, but mainly through small molecules; antibodies offer advantages including higher specificity and longer half-life that small molecules can't achieve.

In 2025, Nabla Bio competes in the AI drug discovery and protein design market with Recursion Pharmaceuticals (RXRX), AbSci (AI antibody design), and Insilico Medicine for AI-powered drug target and antibody discovery, and with traditional antibody discovery companies (AbCellera, Sorrento, Regeneron's VelociSuite) for GPCRs and ion channel antibody programs. The $550M+ partnership revenue from AstraZeneca, BMS, and Takeda validates the platform's commercial appeal to major pharmaceutical companies that need access to the multipass membrane protein antibody capabilities Nabla Bio has built. Radical Ventures' Series A lead reflects deep AI research investment thesis. The 2025 strategy focuses on advancing partnership programs toward the clinic, identifying and developing proprietary pipeline programs in GPCR oncology and neurological disease indications, and expanding the computational protein design platform to additional target classes.

## Frequently Asked Questions

### What is Nabla Bio?
Nabla Bio is a Harvard spinout biotech company specializing in AI-driven generative protein design with a focus on antibodies targeting multipass membrane proteins. The company combines artificial intelligence and wet-lab technologies to develop atomically precise drug designs for challenging therapeutic targets including GPCRs, ion channels, and transporters.

### What products and services does Nabla Bio offer?
Nabla Bio offers an AI protein design platform that enables generative antibody design, specifically targeting difficult-to-drug proteins. Their services include developing GPCR-targeting antibodies, ion channel therapeutics, and transporter protein drugs using their proprietary AI-driven technology.

### Who are Nabla Bio's customers?
Nabla Bio serves major pharmaceutical companies through strategic collaborations. Their current partners include AstraZeneca, Bristol Myers Squibb, and Takeda.

### When was Nabla Bio founded?
Nabla Bio was founded on May 29, 2020. The company was part of Y Combinator's Winter 2020 (W20) batch.

### Where is Nabla Bio located?
Nabla Bio is based in Cambridge, Massachusetts. The company is a Harvard spinout operating in the Boston-area biotech hub.

### How much funding has Nabla Bio raised?
Nabla Bio has raised $37 million in total funding, including a $26 million Series A round in May 2024 led by Radical Ventures. The company is backed by investors including Khosla Ventures, Zetta Venture Partners, and Y Combinator.

### What are Nabla Bio's major achievements?
Nabla Bio has secured strategic collaborations with three major pharmaceutical companies (AstraZeneca, Bristol Myers Squibb, and Takeda), generating over $550 million in upfront and milestone payments alongside royalties. These deals represent significant validation of their AI-driven antibody design platform.

### What technology does Nabla Bio use?
Nabla Bio uses AI-driven generative protein design technology integrated with wet-lab capabilities for atomically precise drug design. Their platform specializes in creating antibodies that target challenging multipass membrane proteins including G protein-coupled receptors, ion channels, and transporters.

### Who founded Nabla Bio?
Nabla Bio was founded by Frances Anastassacos and Surge Biswas. Both founders launched the company as a Harvard spinout in 2020.

### What is Nabla Bio's most recent news?
In May 2024, Nabla Bio raised a $26 million Series A round led by Radical Ventures with continued support from Khosla Ventures and Zetta Venture Partners. The company has also established major pharmaceutical partnerships worth over $550 million in total deal value with AstraZeneca, Bristol Myers Squibb, and Takeda.

## Tags

healthtech, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*